The Cancer Biomarker Market Size was valued at USD 15.9 billion in 2023 and is projected to grow from USD 17.42 Billion in 2024 to USD 27.9 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.06% during the forecast period (2024 - 2032).The increasing usage of cancer biomarkers in drug discovery and development, increased research on cancer biomarkers, technical improvements, and the rising incidence of cancer are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
In June 2023, the FDA introduced a new optional pilot program for specific cancer drugs that are used in conjunction with specific diagnostic tests conducted outside of a living organism. The objective of this program is to assist clinicians in choosing suitable cancer treatments for patients. According to the current standards, an in-vitro companion diagnostic test is a test that gives the necessary information for the safe and efficient use of a related treatment. Under some conditions, the FDA may choose to provide approval for a life-saving medication that necessitates an in-vitro companion diagnostic, even if the associated diagnostic has not yet been authorized for commercialization. During these circumstances, patient treatment decisions are being made using laboratory designed tests (LDTs), which are typically not subject to the agency's evaluation for safety or effectiveness. According to an official statement from the government, the new pilot program aims to tackle issues regarding the lack of accuracy and reliability in the test results provided by LDTs. The FDA will require drug manufacturers to furnish performance data for the tests utilized to recruit patients for the clinical trials that substantiate medicinal approval. After evaluating that information, the FDA will provide suggested minimum performance criteria for similar tests that can be used to identify individuals who can be treated with the approved medicine.
In August 2023, Quest Diagnostics and Envision Sciences announced a partnership to create a new test for prostate cancer biomarkers. This test will aid in diagnosing individuals with more aggressive types of the disease. The announcement was made through separate news releases by Quest Diagnostics and the University of South Australia. The innovative test was created and verified by researchers at the University of South Australia, Adelaide, using the biomarkers Appl1, Sortilin, and Syndecan-1. The biomarker data was previously published in Pathology,3, where 302 samples from radical prostatectomy were evaluated in 114 males diagnosed with prostate cancer. The findings revealed that the biomarker panel led to a 22% increase in the grading of tissue specimens studied and a 20% decrease in grading compared to the usual grading mechanisms based on hematoxylin and eosin-stained (H&E) tissue evaluations. The biomarkers exhibit exceptional sensitivity and specificity in precisely picturing the advancement of the malignancy and validating its grade. This finding has resulted in the commercialization of a diagnostic test specifically designed to assess the stage and aggressiveness of the cancer, as well as to decide the necessity of rapid treatment.
Cancer Biomarker Market Trends
Cancer biomarkers play an important role in companion diagnostics, personalized medicine, and other disease diagnostics, such as illness risk assessment and medication discovery and development. One of the primary reasons likely to boost cancer biomarkers market CAGR during the forecast period is the increasing use of biomarkers in disease diagnostics.
The rising prevalence of cancer around the world is driving up need for early disease detection, moving the industry forward. According to the National Cancer Institute, an estimated 1,735,350 new cases of cancer were diagnosed in the United States in 2018. Furthermore, according to the Cancer Research Fund International, an estimated 18.0 million people worldwide were suffering from in 2018. Lung and breast cancers were the most commonly reported cancers worldwide, accounting for 12.3% of all cases diagnosed in 2018.
The increasing incidence of cancer biomarkers in both developing and developed countries is expected to raise demand for cancer diagnostics and therapy. These factors are expected to drive demand for these Cancer Biomarker market revenue.
The market segments of Cancer Biomarker, based on type, includes Protein Biomarker and Genetic Biomarker. The protein biomarkers segment accounted for the largest share of the market in 2022, mainly due to the increasing research on cancer biomarkers.
Protein biomarkers are detectable flags in a patient's blood that correlate with significant events or indicate specific states in a biological process, such as disease progression. Proteins are important because they are often easier to measure than the complex events they represent. In addition, protein biomarkers approved by the Food and Drug Administration (FDA) include cancer antigen 125 (CA125) in ovarian cancer, carcinoembryonic antigen (CEA) in colon cancer, and prostate-specific antigen (PSA) in prostate cancer.
FIGURE 1: CANCER BIOMARKER MARKET, BY TYPE, 2022 & 2030 (USD BILLION)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The market segments of Cancer Biomarker, based on Application, includes Diagnostic, Prognostic, and Therapeutic. In 2022, the diagnostics segment accounted for the largest share of the cancer biomarkers market. Increased application of cancer biomarkers for companion diagnostics will drive market growth.
The Cancer Biomarker market data has been bifurcated By End-User into Pharmaceutical & Biotechnology Companies, and Diagnostic Companies. Cancer biomarkers are used by pharmaceutical and biotechnology businesses in the development of new cancer therapies, drug discovery, and personalized medicine. These firms invest in biomarker research and development in order to discover new biomarkers that can be used to diagnose and monitor cancer. Whereas Cancer biomarkers are used by diagnostic firms to build cancer diagnostic tests. These firms create and market cancer biomarker tests, which are used by clinicians to diagnose and monitor cancer patients.
By Region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America is estimated to account for a sizable portion of the cancer biomarkers market. Factors such as rising cancer prevalence and activities by key market participants are projected to drive market expansion over the forecast period. The number of cancer patients in the United States has increased significantly. Both men and women can develop breast cancer. Nonetheless, it is usually prevalent in women, and male breast cancer is extremely rare. According to Breastcancer.org, an estimated 287,850 new instances of invasive breast cancer are predicted to be detected in women in the United States in March 2022, along with 51,400 new cases of non-invasive (in situ) breast cancer. Similarly, an estimated 229,200 Canadians were diagnosed with cancer in 2021, according to the Canadian Cancer Statistics 2021, which was issued in November 2021. The rising number of cancer cases is predicted to enhance the use of cancer biomarkers for diagnosis, driving North America Cancer Biomarker market.
Furthermore, the region's high concentration of key players, increasing US Food and Drug Administration approvals, strategic alliances, and high investment in research and development activities are expected to boost the market. In April 2022, for example, researchers at Clarkson University in New York discovered a group of protein biomarkers that could be used to screen for breast cancer in breast milk or blood serum. The biomarkers were discovered for invasive ductal carcinoma (IDC), a type of breast cancer that is one of the most common. However, the researchers claim that their method could also be used to find biomarkers for different types of breast cancer.
Further, the major countries studied in the market report are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: CANCER BIOMARKER MARKET SHARE BY REGION 2022 (%)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe Cancer Biomarker market accounts for the second-largest market share because of the availability of research funds and the growing number of clinical trials in the region. Further, the UK market of Cancer Biomarker held the largest market share, and the Germany market of Cancer Biomarker was the fastest growing market in the North America region
The Asia-Pacific Cancer Biomarker Market is expected to grow at the fastest CAGR from 2022 to 2030. The increasing prevalence of cancer and the growing demand for personalized medicine are among the key drivers of this growth. Moreover, China market of Cancer Biomarker held the largest market share, and the India market of Cancer Biomarker was the fastest growing market in the Asia-Pacific region due to largest population.
Cancer Biomarker Key Market Players & Competitive Insights
The market of Cancer Biomarker is highly competitive, with major market players operating in the market. To increase their market position, these businesses engage in various market developments such as collaborations, partnerships, mergers and acquisitions, and product launches. For example, in October 2021, Illumina announced the $8 billion acquisition of GRAIL, a healthcare business focused on multi-cancer early detection. This acquisition is likely to help Illumina expand its cancer detection and treatment offerings.
In recent years, Cancer Biomarker industry has provided medicine with some of the most significant benefits. The Cancer Biomarker market major player such as Becton Dickinson (U.S.), Merck & Co.Inc. (U.S.), Novartis AG (Switzerland), PerkinElmer Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), Bio-Rad Laboratories (U.S.), Illumina Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Abbott Laboratories (U.S.), GlaxoSmithKline plc. (U.S.), and Others.
Becton, Dickinson and Company (BD) is a multinational medical technology firm that develops, manufactures, and sells medical devices, instrument systems, and reagents. BD, which was founded in 1897, has a long history of invention and has contributed significantly to the progress of healthcare over the years. BD Medical, BD Life Sciences, and BD Interventional are the company's three business segments. BD Medical manufactures medical devices and equipment used in hospitals and clinics, whereas BD Life Sciences manufactures laboratory equipment and reagents used in research and diagnostics. BD Interventional is a company that designs and manufactures medical devices for use in minimally invasive surgical procedures. BD is well-known in the field of cancer biomarkers. Cancer biomarkers are chemicals present in blood and other physiological fluids that signal the presence of cancer. BD offers a variety of cancer biomarker detection and analysis tools, including its
Merck & Co., Inc. (MSD outside the US and Canada) is a multinational biopharmaceutical corporation that develops, manufactures, and sells a wide range of pharmaceutical products and vaccines. Merck, which was founded in 1891, has a long history of invention and has contributed significantly to the progress of healthcare over the years. Merck has a diverse business portfolio that includes pharmaceuticals, animal health, and healthcare services. Its pharmaceuticals division is dedicated to the development and commercialization of products to treat a wide range of diseases and disorders, including cancer. Merck is also interested in cancer biomarker research. Cancer biomarkers are chemicals present in blood and other physiological fluids that signal the presence of cancer. Merck is working on the creation of new cancer biomarkers as well as medications that target specific biomarkers in cancer cells. The company's cancer research initiatives are aimed at enhancing cancer diagnostics, predicting treatment response, and identifying potential new cancer therapy targets.
Key Companies in the market of Cancer Biomarker includes
Becton Dickinson (U.S.)
Merck & Co.Inc. (U.S.)
PerkinElmer Inc. (U.S.)
F. Hoffmann-La Roche AG (Switzerland)
Bio-Rad Laboratories (U.S.)
Illumina Inc. (U.S.)
Thermo Fisher Scientific Inc. (U.S.)
Novartis AG (Switzerland)
Abbott Laboratories (U.S.)
GlaxoSmithKline plc. (U.S.)
Cancer Biomarker Industry Developments
June 2022: Nonagen Bioscience, a cancer diagnostics business, has announced that its Oncuria immunoassay for bladder cancer has received CE marking. Oncuria is the first multiplex urine test of its kind, detecting 10 biomarkers in pee that are linked to the presence of bladder cancer.
June 2022: Tempus, a leader in artificial intelligence and precision medicine, announced the addition of xF+, a new non-invasive, liquid biopsy panel of 523 genes focused on pathogenic mutations in cell-free DNA, to its comprehensive genomic profiling capabilities. It is capable of measuring blood-based tumor mutational burden (bTMB) and microsatellite instability (MSI), both of which are predictive indicators for response to certain cancer immunotherapies.
Protein Biomarker
Genetic Biomarker
Diagnostic
Prognostic
Therapeutic
Pharmaceutical & Biotechnology Companies
Diagnostic Companies
North America
Asia-Pacific
China
Japan
India
Australia
South Korea
Australia
Rest of Asia-Pacific
Rest of the World
Middle East
Africa
Latin America
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 15.9 billion |
| Market Size 2024 | USD 17.42 billion |
| Market Size 2032 | USD 27.9 billion |
| Compound Annual Growth Rate (CAGR) | 6.06% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018 - 2021 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Application, End User and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and Rest of the World |
| Countries Covered | The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Becton Dickinson (U.S.), Merck & Co.Inc. (U.S.), Novartis AG (Switzerland), PerkinElmer Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), Bio-Rad Laboratories (U.S.), Illumina Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Abbott Laboratories (U.S.), GlaxoSmithKline plc. (U.S.), and Others. |
| Key Market Opportunities | Increasing Incidences of Cancer Patients Drives the Market Growth in importance of biological and targeted drug therapies High accuracy and reliability |
| Key Market Dynamics | Advancement of cancer drugs research Increased focus towards advanced treatment protocols |
Cancer biomarker Market Highlights:
Frequently Asked Questions (FAQ) :
Global market is expected to expand at 6.06% CAGR from 2024 to 2032.
Adoption of Western lifestyle by developing economies and extensive research on cancer biomarkers are primary drivers .
High costs of cancer treatment is the major factor expected to impede the global market growth.
The Americas is expected to dominate in the global market till 2023 due to investments in cancer diagnosis and high incidence of cancer.
Thermo Fisher Scientific Inc., PerkinElmer, Inc., Bristol-Myers Squibb, Pfizer Inc., Illumina Inc., F. Hoffmann-La Roche AG, Merck & Co., Inc., Becton Dickinson, GlaxoSmithKline plc., QIAGEN N.V, Eli Lilly and Company, Novartis AG, Abbott Laboratories, and Bio-Rad Laboratories are prominent players of the global market.
The Diagnostic segment had the largest share in the global market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
